
This version is available at https://strathprints.strath.ac.uk/60218/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk
Early Awareness and Alert System in Sweden: History and Current Status

ID:
58

Primary Contact:
Irene Eriksson, Stockholm County Council

All Author/Co-Authors:
Irene Eriksson, Stockholm County Council (Primary Presenter)
Björn Wettermark, Stockholm County Council
Marie Persson, Stockholm County Council
Morgan Edström, Region Östergötland
Brian Godman, Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University and Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet
Anna Lindhé, Västra Götalandsregionen
Rickard Malmström, Clinical Pharmacology, Karolinska University Hospital
Helena Ramström, Stockholm County Council
Mia von Euler, Clinical Pharmacology, Karolinska University Hospital
Anna Bergkvist-Christensen, Region Skåne

Abstract Type:
Poster

Abstract Title:
Early Awareness and Alert System in Sweden: History and Current Status

Topic:
2. Policy issues in HTA d. Country-specific HTA

Abstract Summary:
We describe the evolution and the current state of the Swedish Early Awareness and Alert System for new drugs, a national level EAA system successfully implemented in a country with decentralized health care managed by 21 regions. Our work is of interest to countries already having EAA systems in place as well as for those seeking to establish EAA activities.

Introduction:
Over the past decades, early awareness and alert (EAA) activities and systems have gained importance and become a key early health technology assessment (HTA) tool. While a pioneer in HTA, Sweden had no national level EAA activities until recently. We describe the evolution and current status of the Swedish EAA System.

Methods:
This was a historical analysis based on the knowledge and experience of the authors supplemented by a targeted review of published and grey literature as well as documents produced by or relating to the Swedish EAA System. Key milestones and a description of the current state of the Swedish EAA System is presented.
Results:

Initiatives to establish a system for the identification and assessment of emerging health technologies in Sweden date back to the 1980s. Since the 90s, the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) supported the development of EuroScan and was one of its founder members. In the mid-00s, an independent regional initiative, driven by the Stockholm Drug and Therapeutics Committee, resulted in the establishment of a regional horizon scanning unit. By 2009, this work had expanded to a collaboration between the four biggest regions in Sweden. The following year it was further expanded to the national level. Today, the Swedish EAA System carries out identification, filtration and prioritization of new drugs, early assessment of the prioritized drugs, and dissemination of the information. Its outputs are used to select new drugs for inclusion in the Swedish national process for managed introduction and follow-up.

Conclusions:

The Swedish EAA System started as a regional initiative and rapidly grew to become a national level activity. An important feature of the System today is its complete integration into the national process for managed introduction and follow-up of new drugs. The System will continue to evolve as a response both to the changing landscape of health innovations and to new policy initiatives at the regional, national and international levels.

Low and Lower-Middle Income Country (LMIC) Status:

No

Student Status:

Yes

Poster/Oral Presentation Availability :
Tuesday, June 20, Wednesday, June 21

Supplement Publishing Consent:

Yes

Data Use Consent:
I Agree